Author Archives for admin
May 2, 2024 5:08 pm Published by admin Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells Jian Song1, Xiaobo Wang2, Jiaxue Zhu3, Jun Liu4 1Department of Orthopaedics, Shandong Jining No.1 People’s Hospital, Jining, Shandong, 272000, China; 2Department of Orthopaedics, Wendeng Orthopedic and Traumatic Hospital, Weihai, Shan-dong, 264400, China; 3Department of Orthopaedics, No. 3 People’s Hospital Affiliated to Shanghai Jiao [...]
April 24, 2024 3:48 pm Published by admin Daniel Brian Hurley, M.D. passed away August 3, 2023, from dedifferentiated chondrosarcoma at age 50 surrounded by his loved ones. His wife Traci and their three kids Rachel, Sam, and Sarah were the light of his life. His family, including his parents, in-laws, and siblings were very dear to him. In addition to being a [...]
April 24, 2024 3:37 am Published by admin Ryan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7, Jordi Rodon Ahnert [...]
April 24, 2024 3:36 am Published by admin Ryan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7, Jordi Rodon Ahnert [...]
April 22, 2024 4:27 pm Published by admin Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a useful tool for drug development, facilitating drug target discovery, clinical trial patient selection, and clinical correlate analyses to improve the quality and [...]
April 4, 2024 12:36 pm Published by admin Abstract This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2–3 conventional, dedifferentiated, and mesenchymal CS. The diagnosis of CS combines radiological and histological data in conjunction with patient clinical presentations. Conventional CS is the most frequent subtype of CS (85%) and [...]
March 26, 2024 5:39 pm Published by admin Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report Veronika Blum, 1 , † Vanghelita Andrei, 2 , † Baptiste Ameline, 2 Silvia Hofer, 3 Bruno Fuchs, 1 Klaus Strobel, 1 Anna Allemann, 1 Beata Bode, 4 and Daniel Baumhoer 2 , * Author information Article notes Copyright and License information PMC [...]
March 3, 2024 7:46 pm Published by admin Typically after surgery, it is important to know what post-surgical options are available. Making the decision to enroll in a clinical trial is one of those options and maybe one of the most important decisions chondrosarcoma patients and their families will have to make. It is important to know what a clinical trial offers, what [...]
February 25, 2024 9:23 pm Published by admin Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a useful tool for drug development, facilitating drug target discovery, clinical trial patient selection, and clinical correlate analyses to improve the quality and [...]
February 23, 2024 5:38 pm Published by admin Daniel Brian Hurley, M.D. passed away August 3, 2023, from dedifferentiated chondrosarcoma at age 50 surrounded by his loved ones. His wife Traci and their three kids Rachel, Sam, and Sarah were the light of his life. His family, including his parents, in-laws, and siblings were very dear to him. In addition to being a [...]
